James Dejesus, DPM
Foot & Ankle Surgery · Naugatuck, CTNPI 1083727556
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Gramercy Extremity Orthopedics LLC at 37.5% of the total. Reporting peaked in 2019 at $14,466 and has fallen 80.5% since, to $2,817 in 2025. Among foot & ankle surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $184.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gramercy Extremity Orthopedics LLC$15K
- Arthrex$14K
- Treace Medical Concepts, Inc.$4K
- Smith+Nephew$1K
- International Life Sciences$1K
- Stryker$641
- plus $3K from 22 others
Across 7 payments — averaging $3571.43 each. An ownership or investment interest held by the physician or an immediate family member.
- Gramercy Extremity Orthopedics LLC$25K
What the payments were for
- Consulting fees$13,50034%
- Speaking & faculty fees$10,52727%
- Travel & lodging$6,29016%
- Food & beverage$9,21423%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gramercy Extremity Orthopedics LLC | 23 | $14,884 |
| Arthrex | 42 | $14,427 |
| Treace Medical Concepts, Inc. | 24 | $3,923 |
| Smith+Nephew | 27 | $1,382 |
| International Life Sciences | 2 | $1,308 |
| Stryker | 15 | $641 |
| Medtronic(2 entities) | 9 | $576 |
| Amgen(2 entities) | 11 | $402 |
| Gotham Surgical Solutions & Devices, Inc. | 3 | $312 |
| GRT US Holding, Inc. | 11 | $302 |
| Averitas Pharma Inc. | 7 | $254 |
| Organogenesis Inc. | 7 | $233 |
| Bioventus LLC | 10 | $209 |
| Osiris Therapeutics Inc. | 4 | $195 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $125 |
| Polaris Technology Solutions LLC | 1 | $92 |
| Sanara Medtech Inc. | 1 | $79 |
| Melinta Therapeutics, LLC | 4 | $72 |
| Orthofix Medical, Inc. | 1 | $63 |
| Medshape, Inc. | 2 | $44 |
| Merck | 3 | $43 |
| Convatec Inc. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Zimmer Biomet | 1 | $16 |
| Axogen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$2,140
- Lapiplasty$680
- Stravix$485
- Grafix$365
- GRAFIX PL$236
- KRYSTEXXA$230
- Resolute$224
- CITREFIX$157
- TMC SPEEDMTP$149
- Oasis$142
- VARIAX$136
- SONICANCHOR$136
- BRYHALI$125
- LAPIPLASTY SYSTEM 1$118
- Apligraf$116
- Reveal LINQ$112
- Qutenza$111
- GrafixPL$107
- VenaSeal$100
How this compares
$39,706 in reported general payments places this provider in the 95th percentile of 89 foot & ankle surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QutenzaCapsaicin/Skin Cleanser | 13 | $48,369 |
| Ammonium Lactate | 88 | $1,162 |
| Gabapentin | 86 | $869 |
| Ciclopirox | 24 | $772 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 31 | $644 |
| Betamethasone Dipropionate | 15 | $492 |
| Diclofenac Sodium | 15 | $407 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $381 |
| Cefadroxil | 52 | $331 |
| Tramadol Hcl | 28 | $326 |
| Pregabalin | 13 | $310 |
| Terbinafine Hcl | 30 | $230 |
| Mupirocin | 33 | $222 |
| Ibuprofen | 60 | $185 |
| Meloxicam | 102 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GRT US Holding, Inc.Qutenza | $302 | $48,36913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 foot & ankle surgery providers in Connecticut.
Other foot & ankle surgery in Naugatuck
- Betty CarreiraNaugatuck$3K
- Thomas McDonaldEnfield$241K
- Jossie AbrahamNorwalk$152K
- Gabriel GambardellaBloomfield$99K
- David CaminearHamden$47K
- William ProbascoFairfield$26K
- Adebola AdelekeMiddletown$24K
- Rachel AlbrightDarien$14K
- Paulina PiekarskaNorwalk$13K
- Allen FerrucciHamden$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.